Every material Form 8-K KEWAUNEE SCIENTIFIC CORP /DE/ has filed with the SEC since August 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 2, 2026, Kewaunee Scientific agreed to acquire Nycom, Inc., a laboratory design, distribution and installation business, for a base purchase price of $55 million, subject to adjustments tied to Nycom's adjusted EBITDA and other items. The deal is funded with cash, debt expected from PNC Bank, a $20 million subordinated seller note and $5 million of Kewaunee common stock, and it can be terminated if closing does not occur by March 31, 2027, so it adds debt and share issuance that shareholders will weigh against the expected benefits.
Base purchase price of $55 million, with $30 million paid in cash at closing, including $1 million held in escrow
$20 million subordinated seller note and $5 million of common stock issued to the seller, with a 12-month lock-up
Debt financing expected from PNC Bank, National Association, to help fund the cash portion
Outside date of March 31, 2027; expected to close in the fourth quarter of fiscal 2027
Kewaunee Scientific reported first-quarter fiscal 2027 sales of $66.3 million, down 6.7% from a year earlier, and diluted earnings per share of $0.58 versus $1.04. Pre-tax earnings fell 34.7%, partly due to extra compensation expense from settling long-term incentive awards in cash, which the company says will not recur. Backlog rose from April 30, 2026 but remained below its level a year earlier.
Sales were $66.3 million versus $71.1 million; net earnings attributable to the company were $1.7 million versus $3.1 million.
Pre-tax earnings were $2.6 million versus $3.9 million, a decrease of 34.7%.
Backlog rose to $169.0 million on July 31, 2026, from $165.9 million on April 30, 2026, but was $205.0 million on July 31, 2025.
Long-term debt excluding the sale-leaseback obligation fell to $13.8 million from $15.1 million on April 30, 2026.
At its virtual annual shareholder meeting, Kewaunee Scientific reported fiscal 2026 (ended April 30, 2026) revenue of $282.0 million, EBITDA of $22.4 million and net earnings of $9.6 million. Year-end backlog fell to $165.9 million from $214.6 million, which the company attributed mainly to completing several large international projects.
Fiscal 2026 revenue was $282.0 million; EBITDA was $22.4 million, up from $21.6 million in fiscal 2025.
Lab Products Group sales rose 19.8% to $214.9 million; International segment sales rose 9.9% to $67.1 million.
Consolidated backlog was $165.9 million at April 30, 2026, versus $214.6 million a year earlier.
Long-term debt was reduced by about $20 million, and debt-to-equity improved to 0.61-to-1.0 from 0.99-to-1.0.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every KEWAUNEE SCIENTIFIC CORP /DE/ filing is on SEC EDGAR ↗. 8-K briefs of other companies →